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Abstract. The effect of diseases such as cancer and HIV among our societies is evident. Thus, from the mathemati-
cal point of view many models has been developed with the aim to contribute towards understanding the dynamics
of diseases. Therefore, in this paper we believe by extending a system of delay differential equations (DDEs)
model of HIV related cancer-immune system to a system of delay partial differential equations (DPDEs) model of
HIV related cancer-immune dynamics, we can contribute toward understanding the dynamics more clearly. Thus,
we analyse the extended models and use the qualitative features of the extended model to derive, analyse and im-
plement a fitted operator finite difference method (FOFDM) and present our results. This FOFDM is analyzed for
convergence and it is seen that it has has second-order accuracy. We present some numerical results for some cases
of the the model to illustrate the reliability of our numerical method.
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1. Introduction
The connection between HIV/AIDS and certain cancers diseases is not completely under-
stood, even though the link is likely to depend on a weakened immune system. However, it is
understood that most types of cancer begin when healthy cells change and grow out of control,
forming a mass called a tumor. A tumor can be cancerous or benign. A cancerous tumor is
malignant, meaning it can grow and spread to other parts of the body. A benign tumor means
the tumor can grow but will not spread to other parts of the body. Thus we hope and believe that
efforts to cure such diseases are underway all over the world, focusing more on the interface
and similarities between HIV cure and cancer research. Thus, as a way forward, toward under-
standing the connection between HIV/AIDS and certain cancers diseases, Foryś and Poleszczuk
in [9] derived a system of non-linear delay-differential equations (DDEs) model of HIV related
cancer-immune system dynamics as
Tt = r1T (t)− k1T (t)E(t),
Et = r2T (t)+α−µ1E(t)− k1T (t)E(t)+(1− ε)k1T (t− τ)E(t− τ)
−k′2E(t)I(t)− k3E(t)V (t),
It = k′2E(t)I(t)+ k3E(t)V (t)−µ2I(t),
Vt = Nδ I(t)− cV (t),

(1)
where, the subscript t denotes the partial derivative with respect to time t, T (t), E(t), I(t),
V (t) denote concentration of cancer cells, healthy effector cells (mainly CD4+ T-cells), effector
cells infected by the HIV virus, and free HIV viral particles in that order. Since the dynamics
of cancer cells are assumed to be governed by cancer cells proliferation, their interactions with
the immune system, then the term describing the influence of effector cells on cancer cells is
taken proportional to the product of both concentrations [11, 13]. Thus, the parameters r2, α ,
µ1 denote the antigenicity (difference between tumor and normal tissue) of the tumor, normal
rate of the flow of mature effector cells into the region of cancer cells localization [12], rate
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of elimination of effector cells, in that order. It is understood that the process of effector cells
regeneration after the injection of lytic granules into the target cells causes the cytotoxic T -
cells to kill target cells mainly using lytic granules containing perforin, granzymes and T NF ,
by binding to the surface of the target cell. This trigger the extracellular release of perforin
molecules from the granules. Thus, polymerize to form trans-membrane channels which may
facilitate lysis of the target by permitting entry of granzymes which induce apoptotic cell death
through activation of the caspase protease cascade and ultimate fragmentation of nuclear DNA
[7]. As a results, effector cells should regenerate lytic granules to this effect. Thus, the term τ
denotes the time needed by effector cells to regenerate lytic granules and the time required for
some small percentage (ε) to breach into the target T -cells.
The term describing the release of the new free viral particles by the infected cells is multi-
plied by the additional parameter N to represent the number of those particles released by the
single infected cell. Furthermore, Foryś and Poleszczuk in [9] assumed that the rate of change
of the free HIV viral particles is high relative to the rate of change of the concentration of
considered cellular populations. Hence, Foryś and Poleszczuk in [9] assumed that the rate of
change of the free HIV viral particles is high relative to the rate of change of the concentra-
tion of considered cellular populations. Therefore, during the whole process dV/dt ≡ 0, that is
V (t)≡Nδ/cI(t). This implies that the system of non-linear delay differential equations (DDEs)
in equation (1) reduces to the following system of three non-linear delay differential equations
(DDEs)
Tt = r1T (t)− k1T (t)E(t),
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where,




Since their models take no spacial effects, then in this paper we extend the system of DDEs in
equation (2) to a system of delayed partial differential equations (DPDEs) as
Tt−d1∆T = r1T (t)− k1T (t)E(t),





(0, t) = ∂E
∂ν
(0, t) = ∂ I
∂ν
(0, t) = 0,
∂T
∂ν
(x f , t) = ∂E∂ν (x f , t) =
∂ I
∂ν
(x f , t) = 0, on (x, t) ∈Ω× (0,∞),
X j(x,0) = η j(x), on (x, t) ∈ Ω̄× [−τ,0], j = 1,2,3,

(3)
where d1,d2,d3 denote the cancer cells, healthy effector cells, HIV-infected cells constant diffu-
sion coefficients, ∆ denotes the Laplace operator, X j(x, t)= [T,E, I], j = 1,2,3, Ω∈RN denotes
a bounded domain with smooth boundary ∂Ω and ν denotes the outward unit normal on ∂Ω.
The initial function η j(x, t) is Holder continuous on [−τ,0] and the no-flux boundary conditions
are imposed to ensure the exclusion of external effects. More details on reaction rates can be
found in [9].
Many mathematical models such as those in [1, 2, 6, 13, 14, 16, 17, 21] has been derived in
order to shed more light as to how the dynamics of such virus takes place. While the authors
made the utmost efforts to include whatever we could, we would like to apologize if there are
any omissions which are totally unintentional.
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In this paper, our focus is on the model in which the issue of immune reaction against tumor
and HIV to dissemination arising from the work of Foryś and Pleszczuk in [9], in vivo. We also
would like to acknowledge the work done by Nunnari et al. [18], Resclgnow and Delisi [23] and
by Rong et al. [24], where a significant increase in the incidence of neoplasms accompany the
acquired immunodeficiency syndrome (AIDS), a delay in the formation of killer lymphocytes
was introduced to allow tumor development from a single cell, steps between viral infection of
CD+4T cells and the production of HIV−1 visions have been incorporated by an eclipse phase,
an HIV−1 dynamical model was developed which incorporate AIDS-related cancer cells in
which cancer cells, healthy CD4+ T lymphocytes and infected CD4+ T lymphocytes can have
six steady states, in that order.
Assuming that the cancer-immune system interactions dynamics is governed by cancer cells
proliferation and their interaction with the immune system, thus our first aim in this paper is to
present the fact that in the absence of the cancer and HIV infections, the governing dynamics
of the extended model tends to the expected physiological level and derive the corresponding
stability conditions of the extended model. Our second aim is to develop a fitted operator
numerical method, analyse, implement and present our numerical results with regard to the
governing dynamics.
The rest of paper is organized in the following way. In Section 2, we analyse the extended
model, whereas in Section 3 we derive, analyse our numerical method. We present our numeri-
cal results in Section 4 and conclude the paper with Section 5.
2. Mathematical analysis of the model
First and foremost, we verify that the extended model in equation (3) reflects the normal
physiological level (α/µ1) of the healthy effector cells E, as it is determined by Foryś and
Poleszczuk in [9]. To do that, we solve equation (3) in the absence of the cancer cells (T ≡ 0)




−d2∆E +µ1E = α.(4)
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Following the techniques in [4], we have
E(x, t) = u(x)+w(x, t)(5)
where u := f (x) is independent of the time t and satisfies the boundary value problem (BVP)
−d2uxx +µ1u = α, with u′(0) = u′(x f ) = 0,(6)
and w := f (x, t), which satisfies the BVP
wt = d2wxx−µ1w, with w′(0) = w′(x f ) = 0 and w(x,0) =−u(x).(7)
Since the solution for the homogeneous ordinary differential equation (ODE) in equation (6) is















then we let the corresponding particular solution to the ODE in equation (6) to be
up(x) = c3x+ c4,(9)
where, c1,c2,c3,c4, are constants to be determined. Thus,
µ1(c3x+ c4) = α,⇒ µ1c3x+µ1c4 = α.(10)
Equating terms of same coefficients in equation (10), we find c3 = 0 and c4 = αµ1 , which implies
that the solution to the BVP in equation (6) becomes
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Similarly, At x = x f , we find


















































= c2,⇒ c2 = 0.(17)





Let w(x, t) = X(x)T (t), then applying the method of separation of variables [4] to the BVP in
(7), we have


















which is equivalent to
T (t)exp(ρ2t) = c5,(21)
where c5 is a constant of integration. Hence,
T (t) = c5 exp(−ρ2t).(22)
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Thus,










Applying the boundary conditions in equation (7) to the equation in (24), we have























exp(−ρ2t),⇒ c7 = 0.(26)















Hence, for j = 1,2,3, . . . , we have from equation (27) that√
(ρ2−µ1)
d2
x f =± jπ.(28)
This implies that
w(x, t) = c j exp(−ρ2t)sin( jπx) , for j = 1,2,3, . . . .(29)
Thus, in view of the solutions in (18) and (29) the equation in (5) clearly present the fact that
in the absence of the tumor and HIV-infected effector cells, the solution E(t) in equation (5) of
the extended model in equation (3) converges to the normal physiological level α/µ1 as t→∞.
This implies that our extended model in equation (3) reflects the normal physiological level
(α/µ1) of the healthy effector cells E, as it is determined by Foryś and Poleszczuk in [9] for the
model in equation (1).
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Stability analysis of the equilibria when τ = 0
When the regeneration of lytic granules by the effector cells and breaching of some effector
cells into T -cells happens instantaneously, Foryś and Poleszczuk in [9] established that when
there is no HIV-infected cells, the set D = R2+ is invariant for system (3) at the unique strictly
positive steady state (T̄ , Ē) = ( µ1r1−αk1k1(r2−εr1) ,
r1
k1
), which implies that the immune system is capable
to successfully prevent further cancer development. Therefore, for every solution in D there is
E(t)≤max{E(0), r2
εk1




• for ε < r2r1 , then the unique positive steady state (T̄ , Ē) is globally stable in D ,
• for ε > r2r1 there is no positive steady state as T (t)→ ∞, ∀ t→ ∞.
Thus, the rate of tumor growth reflected by the parameter r1 and rate of cancer elimination by the
immune system, reflected by the parameter value k1, plays an integral part in the investigation
of the governing dynamics of our model. When the concentration of HIV-infected effector cells
is present, Foryś and Poleszczuk in [9] showed that the set D = R3+ is invariant for system (3)
at the unique strictly positive steady state (T̄ , Ē, Ī) = ( µ1r1−αk1k1(r2−εr1) ,
r1
k1
,0). That is, if r1 > αk1µ1 , then
(0, αk1
µ1









,0) is locally asymptotic stable,





) is locally asymptotic stable.
Thus, the above facts present that there is no steady state describing the coexistence of the
concentration of cancer and HIV-infected effector cells in vivo, even at the instantaneously
pace.
Stability analysis of the equilibria when τ > 0
In this section we examine the case for the regeneration of lytic granules by the effector cells
and breaching of some effector cells into T -cells require sometimes to take place, with respect
to the governing dynamics in the previous section. In view of the governing dynamics in the
previous section, we see that the steady states for the system in (3) is same as the steady states of
the corresponding reduced system in equation (3). Therefore, it suffices to consider the stability
for the positive steady states of the equation in (3). Thus, for the extended model in equation
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r2− r1 +(1− ε)r1 exp(−λτ) d2− (µ1 + k1T̄ − (1− ε)k1T̄ exp(−λτ)) −k2Ē
0 0 d3− (µ2− k2Ē)
 .
Hence, the characteristic matrix for the steady state for cancer-immune system interactions
with the concentration of HIV-infected effector cells is
det(∆(λ ,τ)) = (d1−λ )[(d2− (µ1 + k1T̄ − (1− ε)k1T̄ exp(−λτ))−λ ](d3− (µ2− k2Ē))−λ )
+k1T̄ [(r2− r1 +(1− ε)r1 exp(−λτ)](d3− (µ2− k2Ē))−λ ),
in which we let
W (λ ,τ) = det(∆(λ ,τ)) = (d3− (µ2− k2Ē))−λ )W2(λ ,τ),
W2(λ ,τ) = P(λ )+Q(λ )exp(−λτ),(30)
where W2 denotes the characteristic quasi-polynomial for the reduced two-variable system in
(3) with I ≡ 0,
P(λ ) = (d1−λ )(d2− (µ1 + k1T̄ )−λ )+(r2− r1)k1T̄ ,
= λ 2 +(µ1 + k1T̄ − (d1 +d2))λ +(r2− r1)k1T̄ +d1d2.
and
Q(λ ) = k1T̄ (1− ε)(−λ + r1),
= −k1T̄ λ + εk1T̄ λ + r1k1T̄ − εr1k1T̄ .
HIV RELATED CANCER-IMMUNE SYSTEM 11
Since exp(−λτ)> 0 for all values of λ and τ , then we have
P(λ )+Q(λ ) = λ 2 +(µ1 + εk1T̄ − (d1 +d2))λ + r2k1T̄ − εr1k1T̄ +d1d2.
However, the Routh-Hurwitz criteria requires that, all the roots of (30) have negative real parts.
This implies that
(d3− (µ2− k2Ē))> 0, (µ1 + εk1T̄ − (d1 +d2))> 0 and r2k1T̄ − εr1k1T̄ +d1d2 > 0,
which is equivalent to
µ2 < k2Ē−d3, (µ1 + εk1T̄ )> d1 +d2, r2k1T̄ +d1d2 > εr1k1T̄ .
This enable us to obtain the following results.
Corollary 2.1. If r2k1T̄ +d1d2 > εr1k1T̄ and
• µ2 < k2Ē − d3, then if ( µ1−αk1k1(r2−εr1) ,
r1
k1
) is stable as a steady state in the two-variable
system, then ( µ1−αk1k1(r2−εr1) ,
r1
k1
,0) is stable as a steady state for system in equation (3),




Since there is no steady state describing the coexistence of the tumor cells with the HIV
infection in vivo and in view of the results in Corollary (), we see that the steady states for the
system in (3) under the governing dynamics are the same as for the governing dynamics without
the infection, then in the next section it suffices to examine the existence of Hopf bifurcation
for the reduced (two-variable) system in equation (3).
Existence of Hopf bifurcation





) is stable for τ = 0. Therefore, for stability
switches we follow the ideas from Cooke and Driessche in [5], that the necessary condition for
stability switches is the existence of purely imaginary eigenvalue
λ = iω, ω > 0 for some threshold value τth.
If iω is an eigenvalue for τth, then
W2(iω,τth) = 0⇒ P(iω) =−Q(iω)exp(iωτth)






F(y) = y2 +Ay+B, y = ω2,
A = ε(2− ε)k21T̄ 2 +2(µ1− r2 + r1)k1T̄ +µ21 −2(µ1 + k1T̄ )d1d2 +d21d22 > 0,
B = (r2− r1(2− ε))(r2− r1ε)k21T̄ 2 > 0,
if r2− r1ε > 0, ε < 1, and if
• r2− r1(2− ε)> 0, then there is no positive roots of F .
• r2− r1(2− ε)< 0, then F has exactly one positive root ȳ.
These above two facts enable us to state the following results.
Theorem 2.1. Assume that the steady state ( µ1−αk1k1(r2−εr1) ,
r1
k1
) exists. Then if
• r2− r1(2− ε)> 0, then (T̄ , Ē) is stable for any positive delay τ > 0.
• r2−r1(2−ε)< 0, then there exists the threshold dealy τth > 0 such that (T̄ , Ē) is stable
for τ < τth, loses stability at τ = τth in which Hopf bifurcation occurs.




cannot recover stability for larger values of τ .
3. Derivation and analysis of the numerical method
In this section, we describe the derivation of the fitted numerical method for solving the
system in equation (3). We determine an approximation to the derivatives of the functions
T (t,x),E(t,x) and I(t,x) with respect to the spatial variable x.
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Let Nx be a positive integer. Discretize the interval [0,x f ] through the points
x0 = 0 < x1 < x2 < · · ·< xNx = x f ,
where the step-size ∆x = x j+1− x j = x f /Nx, j = 0,1, . . . ,Nx. Let T j(t),E j(t),I j(t) denote
the numerical approximations of T (t, j),E(t, j), I(t, j), then we approximate the second order
spatial derivative terms by
∆T (t,x j)≈
T j+1−2T j +T j−1
φ 2T
, ∆E(t,x j)≈
E j+1−2E j +E j−1
φ 2E
, ∆I(t,x j)≈









































It is not that difficult to see that φT → ∆x, φE → ∆x and φI → ∆x, as ∆x→ 0.
Let Nt be a positive integer and ∆t = H/Nt where 0 < t < H. Discretizing the time interval
[0,H] through the points
0 = t0 < t1 < · · ·< tNt = H,
where
tn+1− tn = ∆t, n = 0,1, . . . ,(Nt−1).




















ψT = (1− exp(−r1∆t)−1)/r1, ψE = (exp(µ1∆t)−1)/µ1, ψI = (exp(µ2∆t)−1)/µ2,
where we see that ψT → ∆t, ψE → ∆t and ψI → ∆t as ∆t→ 0.
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The denominator functions in (31) and (32) are used explicitly to remove the inherent stiffness
in the central finite derivatives parts and are derived by using the theory of nonstandard finite
difference methods, see, e.g., [15, 19, 20] and references therein.

























+ r2T nj −µ1E nj − k1T nj E nj +(1− ε)k1(HT )nj(HE)nj












+ k2E nj I
n
j −µ2I nj ,























E 0j = 780, T
0








j ≈ T (tn− τ,x j) and (HE)nj ≈ E(tn− τ,x j),(34)
are the history functions corresponding to the equations in T and E for j = 1,2, . . . ,Nx− 1,
n = 0,1, . . . ,Nt−1.
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Consequently, the system in equation (35) can be written as a tridiagonal system given by






T nj − k1T nj E nj ,








E nj − k1T nj E nj +(1− ε)k1(HT )nj(HE)nj
−k′2E nj I nj +α,


















































On the interval [0,τ] the delayed arguments tn− τ belong to [−τ,0], and therefore the delayed
variables in equation (36) are evaluated directly from the history functions T 0(t,x),E0(t,x) as
(HT )
n
j ≈ T 0(tn− τ,x j) and (HE)nj ≈ E0(tn− τ,x j),(37)
and equation (36) becomes






T nj − k1T nj E nj ,








E nj − k1T nj E nj
+(1− ε)k1T 0(tn− τ,x j)E0(tn− τ,x j)− k′2E nj I nj +α,


















j for 1≤ n≤ s. Up to this stage, we interpolate the data
(t0,T 0j ), (t1,T
1
j ), . . . ,(ts,T
s




j ), . . . ,(ts,E
s
j ),
using an interpolating cubic Hermite spline ϕ j(t). Then
T nj = ϕT (tn,x j) and E
n
j = ϕE(tn,x j),
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for all n = 0,1, . . . ,s and j = 1,2, . . . ,Nx−1.
For n = s+ 1,s+ 2, . . . ,Nt − 1, when we move from level n to level n+ 1 we extend the
definitions of the cubic Hermite spline ϕ j(t) to the point (tn +∆t,T nj ,E
n
j ). Then the history
terms (HT )nj and (HE)
n




j ≈ (ϕT ) j(tn− τ) and (HE)nj ≈ (ϕE) j(tn− τ),(39)
and equation (33) becomes






T nj − k1T nj E nj ,








E nj − k1T nj E nj +(1− ε)k1ϕT (tn− τ)ϕE(tn− τ)
−k′2E nj I nj +α,














ϕT (tn− τ) = [(HT )n1,(HT )n2 . . . ,(HT )nNx−1]
′, ϕE(tn− τ) = [(HE)n1,(HE)n2 . . . ,(HE)nNx−1]
′.
Our FOFDM is then consists of equations (33)-(41). Re-writing the scheme in (41) in a form of
a system of equations
AT T = FT ,
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j are given by
(ςT )
n
j = (AT T )
n














maxn, j |T nj −T nj | ≤ ||A
−1
T ||maxn, j |ςT |,
maxn, j |Enj −E nj | ≤ ||A
−1
E ||maxn, j |ςE |,
maxn, j |Inj −I nj | ≤ ||A
−1




maxn, j |ςT | ≤ ∆t2
∣∣Ttt(ξ ,x j)∣∣+ (∆x)212 |Txxxx(tn,ζ )| ,
maxn, j |ςE | ≤ ∆t2
∣∣Ett(ξ ,x j)∣∣+ (∆x)212 |Exxxx(tn,ζ )| ,
maxn, j |ςI| ≤ ∆t2
∣∣Itt(ξ ,x j)∣∣+ (∆x)212 |Ixxxx(tn,ζ )| ,

(44)
tn−1 ≤ ξ ≤ tn+1,x j−1 ≤ ζ ≤ x j+1 and by the result in [25], we obtain
||A−1T || ≤ ΞT ,
||A−1E || ≤ ΞE ,
||A−1I || ≤ ΞI.

(45)
Using (46) and (45) into (43), we obtain the following results.
Theorem 3.1. Let FT (x, t),FE(x, t),FI(x, t) be sufficiently smooth functions so that
T (x, t),E(x, t), I(x, t)∈C1,2([1,Nx]×[1,Nt ]). Let (T nj ,E nj ,I nj ), j = 1,2, . . .Sx,n= 1,2, . . .Nt be
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Then there exists ΞT ,ΞE ,ΞI independent of the step sizes ∆t and ∆x such that
maxn, j |T nj −T nj | ≤ ΞT [
∆t
2
∣∣Ttt(ξ ,x j)∣∣+ (∆x)212 |Txxxx(tn,ζ )|],
maxn, j |Enj −E nj | ≤ ΞE [
∆t
2
∣∣Ett(ξ ,x j)∣∣+ (∆x)212 |Exxxx(tn,ζ )|],
maxn, j |Inj −I nj | ≤ ΞI[
∆t
2
∣∣Itt(ξ ,x j)∣∣+ (∆x)212 |Ixxxx(tn,ζ )|].

(46)
Hence, we conclude our analysis with the following result.
Theorem 3.2. (Fatunla [8], Trefethen [26]) A difference scheme is said to be convergent if and
only if it is consistent and stable.
4. Numerical results and discussions
Taking the diffusion constants d1,d2,d3 in [10−1,10−20], using the parameter values in Table
1, and using the fact that the regeneration of lytic granules by the effector cells and the breaching
of some effector cells into T -cells requires time τ to happened, then we present our numerical
solutions for the case when τ 6= 0 and τ = 0 as follows. In (a) and (b), we have the situation
when a host is infected by the concentration of cancer cells only, (c) and (d), the situation when
a host is infected by the concentrations of cancer cells, then becomes infected with HIV at a
later stage, whereas in (e) and (f) we have the case when a host is infected with HIV then at a
later stage becomes infected with cancer too.
In (a) we see the immune cells raising to their steady states, whereas the cancer cells drasti-
cally being reduced to nothing. We also see similar interactions in (b) even though the immune
healthy effector healthy cells start with a slow decrease due to the infection inflicted by the
cancer cells, before it converges to its steady state.
In (c) and (d) the situation which is depicted in (a) and (b) changes, due to the introduction of
the HIV-infected effector cells. In (c), we see healthy effector cells raises before the introduction
of the HIV-infected effector cells. We also see that HIV-infected cells raised to some magnitude
which causes the healthy cells to drastically drop to a low steady state. As soon as the healthy
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effector cells drops low so does the HIV-infected cells. This we see that it paves the way for
cancer cells to raise. In (d) we see similar behaviors to the behaviors in (c) at a magnified pace.
In (e) we see HIV-infected cells raising causing the healthy immune cells to flactuate towards
their steady states. Such flactuations can be seen in the behaviour of the HIV-infected cells
due to the strength of the immune healthy cells. However, the introduction of cancer cells
weaken the immune healthy cells which in turn subject the HIV-infected cells to raise high.
The dynamics in (f) are straight forward a except that the HIV-infected cells eventual converge
to their low staedy state. This is due to the impaired healthy immune healthy cells by both
infections.
5. Conclusion
In this paper, we investigated the extended model arising in HIV related cancer-immune
system dynamics and we were able to show that the physiological level of our extended model
coincides with the original model in equation (1). Our numerical results present a clear fact
played by the inclusion of a delay term (τ) in the dynamics of our extended model. We also
see the crucial agreement of our results that the healthy immune system is able to successfully
prevent the development of the cancer infection in a host and unable to do so when a host is
infected by an additional infection, such as HIV. However, when a host is infected with HIV our
results clearly shows that the healthy immune system is unable to prevent further development
of the HIV-infected cells. Consequently, our results also present the fact that the weakened
immune system cannot prevent the growth of the cancerous cells. Thus, the work in this paper,
should be seen as the first attempt to provide an in depth information about the growth rate
of tumor cells is relatively larger than the rate of elimination of cancerous cells by the healthy
immune system..
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TABLE 1. The ranges of parameters values and corresponding references
r1[13] k1[13] r2 α/µ1[10] k′2[13] k3[6]
0.05∼ 0.5 10−5 ∼ 10−3 0∼ 0.05 800∼ 1200 10−5 ∼ 5×10−4 2.4×10−5
µ2[13] δ [21] c[21] µ1 ε[2] N[6]
0.3 0.3∼ 0.7 2.1∼ 3.8 0.03 0.1 100∼ 2000
r1 k1 r2[11] α/µ1 k′2 k3
0.1 10−4 0.03 800 5×10−5 2.4×10−5
µ2 δ c µ1[11] ε N
0.3 0.3 3.8 0.03 0.1 275
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FIGURE 1. Numerical solution of the concentrations of cancer, HIV-infected
and healthy effector cells interaction model. Plots (a-f) correspond to the con-
centrations of cancer and healthy effector cells with delay = 5, without delay,
with introduction of HIV-infected effector cells with delay = 5, with introduc-
tion of HIV-infected effector cells without delay, with the introduction of the
concentration of cancer cells with delay = 5, and the introduction of the concen-
tration of cancer cells without delay. Parameters are given in Table 1
